Neurocrine Biosciences (NBIX) EBITDA Margin Growth (1y) (2011 - 2026)
Neurocrine Biosciences (NBIX) EBITDA Margin Growth (1y) (2011 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 38.34 Bn | 34.60 Bn | 1.97 Bn | 304.00 |
| 2 | Zoetis | 33.27 Bn | 31.33 Bn | 1.62 Bn | -157.00 |
| 3 | United Therapeutics | 23.75 Bn | 21.60 Bn | 648.10 Mn | -650.00 |
| 4 | Aurora Cannabis | 17.11 Bn | 17.03 Bn | 33.43 Mn | -3,172.00 |
| 5 | Neurocrine Biosciences | 16.37 Bn | 15.05 Bn | 800.70 Mn | 2,080.00 |
| 6 | Elanco Animal Health | 11.78 Bn | 11.35 Bn | 785.00 Mn | 152.00 |
| 7 | Alkermes | 7.05 Bn | 6.54 Bn | -116.06 Mn | -17,785.00 |
| 8 | Lantheus Holdings | 6.49 Bn | 5.99 Bn | 230.92 Mn | -583.00 |
| 9 | Hims & Hers Health | 6.19 Bn | 5.44 Bn | 396.79 Mn | -2,472.00 |
| 10 | Liquidia | 5.63 Bn | 5.40 Bn | 121.79 Mn | 118,171.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 2,080.00 |
| Dec 31, 2025 | 403.00 |
| Sep 30, 2025 | 365.00 |
| Jun 30, 2025 | 527.00 |
| Mar 31, 2025 | -577.00 |
| Dec 31, 2024 | -1,532.00 |
| Sep 30, 2024 | 625.00 |
| Jun 30, 2024 | -1,057.00 |
| Mar 31, 2024 | 2,469.00 |
| Dec 31, 2023 | 727.00 |
| Sep 30, 2023 | -66.00 |
| Jun 30, 2023 | 12,045.00 |
| Mar 31, 2023 | -1,901.00 |
| Dec 31, 2022 | 2,610.00 |
| Sep 30, 2022 | 970.00 |
| Jun 30, 2022 | -11,354.00 |
| Mar 31, 2022 | -1,120.00 |
| Dec 31, 2021 | -14,279.00 |
| Sep 30, 2021 | 3,032.00 |
| Jun 30, 2021 | -1,377.00 |